This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
20 Jun 2022

SynBalance: Scientifically-Backed and Innovative Lifewide Probiotics

SynBalance life wide probiotics

2022 sees the birth of SYNBALANCE Srl, the new subsidiary company of ROELMI HPC, aiming to become a leader in the biotech industry. The new company business will mainly focus on discovering and unlocking the health-enhancing possibilities of microbiota world.

With a distinct identity and management, as of January 2022, SynBalance is the right partner for developing probiotic-based products backed by clinical evidence.

The strategic creation of SynBalance naturally comes by the need of giving the fair value and facilitating the growth of such a dynamic market, both in terms of dedicated R&D investments and specialized in-house expertise. As part of ROELMI HOLDING, the new company will share the group commitment to bring sustainable and scientifically-backed ingredients to the market, as indicated by the voluntary CSR approach named N.I.P.® program.

With a vision for a sustainable future for all human kind, SynBalance's mission is to deliver highly scientifically-evidenced probiotic solutions, taking care of people's health through the modulation of the gut microbiota. Always committed to scientific research, to innovation and to the market, SynBalance designs, develops and manufactures high-quality proprietary probiotic strains belonging to Lactobacilli and Bifidobacteria, customized or studied premixes and ready-to-go supplements. Technical dossiers are based on in-vitro, ex-vivo & clinical results, supported by stability data and specific formulation targeting consumers’ needs.

At SynBalance we celebrate continuous innovation, our team characterized by well-crafted expertise in the field of probiotics allows us to offer proactive products to help final consumers in their journey, with particular attention to increasingly competitive prospects. Innovations that balance health with time-to-market, responding to the fast-changing and trend-oriented nutraceutical industry.

SynBalance's strategy focuses on defined functional areas such as gut-skin axis, reduction of cardiometabolic risk, immune-modulation and gut-brain axis. A deeper attention is dedicated to target population likewise women, children and elderly. In terms of technological progress, SynBalance aims at providing solutions for new markets such as functional food and expanding in countries challenging for probiotics: with this purpose, the company is investigating different microencapsulation processes (HUGbiotics® line) to improve viability with respect to temperature, osmotic pressure, pH and humidity. Moreover, SynBalance keeps an interest on post-biotics potential as a complementary approach to alive probiotics. In fact, studies on heat-killed bacteria (SynbiOFF®) are currently ongoing to discover new functional domains and characterize alternative mechanisms of action. 

Among the most science-backed probiotic complexes, we can list:

- SynBalance® AllergAway: fighting sensitization reactions

- SynBalance® CholDown: cholesterol control

- SynBalance® DefensePlus: body natural defenses

- SynBalance® Femme: protecting vaginal health

- SynBalance® HappyBelly: dysbiosis & intestinal discomfort in children

- SynBalance® KeepCalm: stress relief

- SynBalance® MetSyn: metabolic syndrome

- SynBalance® ProBeautyShield: skin health

- SynBalance® SmilinGut: IBS and gastrointestinal disorders

- SynBalance® Wellderly: elderly people

Mentioned Companies
SYNBALANCE SRL
View company profile